On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...

PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured in a Watchlist Interview ...

Companies this past month announced many new products and services that use artificial intelligence to automate complex processes, secure data and improve care coordination and interoperability ...

MONTRÉAL, QC / ACCESS Newswire / November 6, 2025 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and development of vertical market software businesses, is ...

Dementia poses an increasing global health challenge, and the introduction of new drugs with diverse activity profiles ...

Anumana, a leader in AI-powered cardiovascular diagnostics, today announced new groundbreaking clinical data presented at the American Heart Association (AHA) Scientific Sessions 2025. Among the ...

At ProMedica, growing knowledge about AI technology among leadership is helping to drive adoption of AI tools in clinical care.

QKS Group named ProcessUnity, The Third-Party Risk Management Company, as a SPARK Leader in their analysis of the SPARK Matrixtm: Vendor Risk Management, 2025 market. The QKS Group SPARK Matrixtm ...

CFO and COO Mark Hirschhorn reported, "in the third quarter, we delivered results ahead of expectations for both revenue and adjusted EBITDA, reflecting stronger subscription retention, increased ...

Eli Lilly and Novo are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs. Blackstone Life Sciences will pay Merck $700 million for ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced an update on its ongoing adult clinical study in the US.